Tuesday June 18, 2019

Diabetes Can Contribute to Infertility: Experts

The global health body also estimates that 80 per cent of diabetes deaths occur in low and middle-income countries and projects that such deaths will double between 2016 and 2030

0
//
Diabetes
Representational image. Pixabay

Diabetes, commonly described as a “lifestyle disease”, can contribute to infertility in both women and men, warn health experts.

“Diabetes can cause infertility in both men and women. Both sexes are at equal risk of infertility,” S.K. Wangnoo, endocrinologist at Indraprastha Apollo Hospitals, told IANS.

Infertility affects up to 15 per cent of reproductive-aged couples worldwide. According to an estimate by the World Health Organization (WHO), the overall prevalence of primary infertility in India is between 3.9 per cent to 16.8 per cent.

“Diabetes in men damages DNA of the sperm and leads to reduced number of sperms and reduced motility of sperms which leads to infertility. Although having diabetes does not necessarily make men infertile, it could make them less fertile,” added Roopak Wadhwa, Consultant at Fortis Hospital, New Delhi.

On the other hand, diabetes in women is associated with polycystic ovary syndrome (PCOS) and other autoimmune diseases that can lead to infertility.

“Diabetes causes a lack of glucose control in the body which, in turn, can make the implantation of the fertile egg in the uterus difficult. Therefore, the chances of miscarriage in diabetic women increase between 30-60 per cent,” Wadhwa explained.

Another WHO report had stated that India had 69.2 million people living with diabetes in 2015.

Diabetes
Representational image. Pixabay

By 2030, nearly 98 million people in India may have Type-2 diabetes, according to a study published in the Lancet Diabetes and Endocrinology journal last year.

While diabetic patients can always try parenthood, the risk of passing on the sugar disease to the child is approximately 50 per cent high, Wangnoo stated.

“It can also cause intra-uterine growth retardation (IUGR) and congenital anomalies. IUGR is a condition where an unborn baby is smaller than it should be because it is not growing at a normal rate inside the womb,” Wadhwa added.

Furthermore, he noted that diabetic mothers are at high risk of premature deliveries, abortions and perinatal (during birth) complications.

Also Read- Social Networking Giant Facebook Allows Ads to Promote Anti-vaccine Content

High diabetes can be risky for both mother and child. The experts suggest that maintaining a good lifestyle, an ideal body weight, keeping sugars within target range, avoiding smoking and alcohol and excessive work related stress are some of the preventive measures.

Besides infertility, diabetes can also raise the risk of cardiovascular and lung disease, arthritis, osteoporosis. An estimated 3.4 million deaths are caused due to high blood sugar, according to the WHO.

The global health body also estimates that 80 per cent of diabetes deaths occur in low and middle-income countries and projects that such deaths will double between 2016 and 2030. (IANS)

Next Story

Researchers Find Drug to Delay Type-1 Diabetes by Two Years

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine

0
Diabetes
Representational image. Pixabay

In a first, researchers have found that a treatment affecting the immune system effectively slowed the progression to clinical Type-1 diabetes in high risk individuals by two years or more.

“The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment,” said Lisa Spain, Project Scientist from US National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The study, involving treatment with an anti-CD3 monoclonal antibody (teplizumab), was conducted by Type 1 Diabetes TrialNet, an international collaboration aimed at discovering ways to delay or prevent Type-1 diabetes.

Participants were randomly assigned to either the treatment group, which received a 14-day course of teplizumab, or the control group, which received a placebo.

All participants received glucose tolerance tests regularly until the study was completed, or until they developed clinical Type-1 diabetes – whichever came first.

During the trial, 72 per cent of the people in the control group developed clinical diabetes, compared to only 43 per cent of the teplizumab group.

diabetes
“Although Type-1 and Type-2 diabetes in parents are well-established risk factors for diabetes, we show that gestational diabetes mellitus may be a risk indicator for diabetes in the mother’s children before age 22,” . Pixabay

The median time for people in the control group to develop clinical diabetes was just over 24 months, while those who developed clinical diabetes in the treatment group had a median time of 48 months before progressing to diagnosis.

“The difference in outcomes was striking. This discovery is the first evidence we’ve seen that clinical Type-1 diabetes can be delayed with early preventive treatment,” Spain added.

Type-1 diabetes develops when the immune system’s T cells mistakenly destroy the body’s own insulin-producing beta cells.

Also Read- Cutting Sodium Intake May Prevent 94 Million Premature Deaths From CVD

Insulin is needed to convert glucose into energy. Teplizumab targets T cells to lessen the destruction of beta cells.

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine. (IANS)